Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Beginner level

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accounts payable 2.82 1.86 2.03 1.94 2.51
Accrued payroll and related costs 2.33 2.23 2.19 2.20 2.38
Accrued clinical trial expense 0.96 1.21 1.38 1.32 1.57
Accrued sales-related charges, deductions, and royalties 1.68 1.56 2.22 2.29 3.49
Income taxes payable 0.33 0.18 0.00 3.38 0.00
Other accrued expenses and liabilities 2.04 1.40 1.48 1.50 1.54
Accrued expenses and other current liabilities 7.34% 6.58% 7.27% 10.69% 8.99%
Finance lease liabilities, current portion 0.00 0.00 0.00 1.86 0.03
Deferred revenue from Sanofi, current portion 2.67 2.10 2.03 1.65 1.81
Deferred revenue, other, current portion 1.33 1.75 1.62 1.67 0.93
Convertible senior notes, current portion 0.00 0.00 0.00 0.00 0.19
Current liabilities 14.16% 12.30% 12.96% 17.80% 14.46%
Finance lease liabilities, excluding current portion 4.82 6.04 8.03 5.04 6.47
Deferred revenue from Sanofi 3.44 2.38 4.34 7.22 10.39
Deferred revenue, other 0.74 1.58 2.84 4.69 1.46
Other noncurrent liabilities 1.93 3.08 1.74 1.44 2.06
Noncurrent liabilities 10.93% 13.08% 16.94% 18.39% 20.38%
Total liabilities 25.10% 25.37% 29.90% 36.20% 34.84%
Preferred Stock, $.01 par value; issued and outstanding - none 0.00 0.00 0.00 0.00 0.00
Class A Stock, convertible, $.001 par value 0.00 0.00 0.00 0.00 0.00
Common Stock, $.001 par value 0.00 0.00 0.00 0.00 0.00
Additional paid-in capital 29.91 33.33 40.08 43.45 55.26
Retained earnings 49.85 44.78 33.62 25.07 15.20
Accumulated other comprehensive income (loss) 0.14 -0.10 0.01 -0.18 0.15
Treasury Stock, at cost -5.00 -3.38 -3.61 -4.53 -5.46
Stockholders’ equity 74.90% 74.63% 70.10% 63.80% 65.16%
Total liabilities and stockholders’ equity 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc.’s current liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc.’s noncurrent liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc.’s total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc.’s stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2017 to 2018 and from 2018 to 2019.